GermanyGermany

New OECD-compatible data for German biotech companies

08.06.2009

Berlin – According to the latest figures from biotechnologie.de, Germany’s biotech sector has grown in the last year. A survey conducted by the information platform received an 85% response rate from the German bio­tech companies taking part. It revealed that turnover among the country’s 500 dedicated companies climbed 9?% to over a2bn in 2008, while R&D expenditure remained stable at approximately a1bn (+1.1%). The number of staff employed rose slightly. The survey was conducted on behalf of the German Research Ministry in early 2009. In compliance with the guidelines laid out by the Organisation for Economic Co-operation and Development (OECD), the study was conducted to help provide insights into the economic situation of the German bio-

tech landscape.

Importance of biotechnology

on the rise

The study identified a total of 500 companies in Germany that dealt either exclusively or predominantly with biotechnological procedures. These companies had 14,450 employees on their books (compared to 14,360 in 2007).
The importance of the field is also increasing in companies where biotechnology is just one business activity among others, according to the study. In the 92 companies that fell into this category – among them pharma firms, chemical enterprises, and seed manufacturers – 15,520 people were employed in bio­tech-related areas. That brings the total number of staff employed in commercial biotechnology in Germany to about 30,000, 1.4?% more than in 2007.

A maturing market

The average German biotech company is 8.6 years old. Roughly a third have been active for more than 10 years, whereas just 13% were founded in the last 3 years.
Many of the respondents set up shop in the wake of the 1996 Bio­Regio competition (1997-2001). About 60% of all biotech companies still operating today began their business activities during this period. The competition is also still visible in the current distribution of companies. Three of Germany’s four largest biotechnology clusters are located in the winning regions of the funding contest that was initiated by former German Research Minister Jürgen Rüttgers, are still booming. The Munich area and Rhineland/Cologne region were at the top of the list, along with Berlin-Brandenburg and Baden-Wurttemberg (see figure).
Most of the other companies active in the sector are situated in the federal states of North Rhine-Westphalia, Hessen and Lower Saxony, reflecting the strong industrial focus of the western part of the country.

GermanyGermany

07.03.2012

The first of February marked a milestone for Leverkusen-based Bio­frontera AG in more ways than one. It was the first day that Ameluz, the firm’s first approved product, could be sold in German pharmacies. It was also the date...

GermanyGermany

07.03.2012

Darmstadt – German pharmaceutical and chemical company Merck KGaA has set a downbeat tone for 2012. CEO Karl-Ludwig Kley said the recently launched cost-cutting programme and tough economic conditions will weigh on profits this...

GermanyGermany

05.03.2012

Mainz/Leuna – Two biotech concepts were amongst the winners of the recent third round of the Excellence Cluster initiative, which is funded by the German Ministry for Research. In Mainz the champagne corks popped especially loud...

GermanyGermany

05.03.2012

German Merck KGaA has closed a licencing agreement with US-based Threshold Pharmaceuticals Inc. The cooperation centres around the hypoxia­-activated drug TH-302, which is currently being studied in a global Phase III study....

GermanyGermany

29.02.2012

Munich – Looking back with satisfaction and bent on a prize for good behaviour, German biopharmaceutical company Wilex AG reported yesterday on the fiscal year 2011 and outlined the shores in sight. The 2011 total revenue was...

GermanyGermany

17.02.2012

Brussels – European cartilage researchers intensify their cooperation. The 'gristle network' comprises scientists from Belgium, France, Germany and Luxembourg. Its members plan to meet regularly to exchange views and information...

27.01.2012

Thousand Oaks/Munich - Bling bling for blinatumomab. It is a compliment for the European life sciences scene and sad news at the same time. Amgen Inc., the world's largest biotechnology company, agreed to buy Micromet Inc., an...

GermanyGermany

20.01.2012

Martinsried - SHELTER is responsible for the fact that the stocks of 4SC behaved like a rodeo horse on Thursday. The shares rose in several stages up to 63%, only to settle at a mere 43% rise at the end of the day. SHELTER is a...

GermanyGermany

17.01.2012

Ludwigshafen – BASF Plant Science GmbH, the agrochemistry and biotech arm of the world-largest chemistry company, thinks that it has outstayed its welcome in Europe. Over the next two years, most of the green biotechnology...

GermanyGermany

10.01.2012

Munich - It is the accolade for Micromet. The German company, which is listed on the U.S. stock exchange, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the renowned US...

Displaying results 1 to 10 out of 454

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-germany/article/new-oecd-compatible-data-for-german-biotech-companies.html

Events

All Events

Stock list

All quotes

TOP

  • ADDEX3.51 CHF12.14%
  • STRATEC BIOMEDICAL41.09 EUR4.55%
  • MEDIGENE4.00 EUR2.30%

FLOP

  • CYTOS0.18 CHF-5.26%
  • MOLOGEN6.60 EUR-2.22%
  • SANTHERA86.95 CHF-1.92%

TOP

  • PAION3.22 EUR35.3%
  • CO.DON3.14 EUR28.2%
  • FORMYCON8.20 EUR16.6%

FLOP

  • CYTOS0.18 CHF-30.8%
  • EVOTEC3.10 EUR-15.8%
  • 4SC1.04 EUR-15.4%

TOP

  • SANTHERA86.95 CHF2112.5%
  • PAION3.22 EUR228.6%
  • CO.DON3.14 EUR223.7%

FLOP

  • CYTOS0.18 CHF-95.4%
  • 4SC1.04 EUR-45.0%
  • MOLOGEN6.60 EUR-44.0%

No liability assumed, Date: 30.09.2014


Current issue

All issues

Product of the week

Products